NYSE$MRK
Merck & Co. · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Merck reported an increase in Q4 revenue driven by oncology and animal health, and announced spin-off of Women’s Health, trusted Legacy Brands and Biosimilar products.
Merck's Q4 2019 results showed strong growth in pharmaceutical sales, driven by oncology, particularly KEYTRUDA, and animal health, boosted by the Antelliq acquisition. The company's GAAP EPS was $0.92, and non-GAAP EPS was $1.16. Merck also announced its plan to spin off its Women’s Health, trusted Legacy Brands, and Biosimilar products into a new company.
- Fourth-quarter pharmaceutical sales increased 7% to $10.5 billion.
- KEYTRUDA sales were $3.1 billion for the quarter.
- Animal Health sales totaled $1.1 billion, an increase of 8%.
- GAAP EPS was $0.92 for the fourth quarter, and non-GAAP EPS was $1.16.
Headline financials
Revenue & EPS history
Merck · Revenue · Quarterly
$11.9B
Revenue by segment
Merck · $11.6B total across 2 segments · Q4 2019
- Pharmaceutical$10.5B—90.5%
- Animal Health$1.1B—9.5%
Forward guidance
Merck anticipates full-year 2020 revenue to be between $48.8 billion and $50.3 billion. Merck expects full-year 2020 GAAP EPS to be between $4.57 and $4.72. Merck expects full-year 2020 non-GAAP EPS to be between $5.62 and $5.77.
Tailwinds
- Full-year 2020 revenue to be between $48.8 billion and $50.3 billion.
- Full-year 2020 GAAP EPS to be between $4.57 and $4.72.
- Full-year 2020 non-GAAP EPS to be between $5.62 and $5.77.
- Guidance includes a negative impact from foreign exchange of less than 1% on revenue.
- Non-GAAP range excludes acquisition- and divestiture-related costs and costs related to restructuring programs.
Headwinds
- Guidance includes a negative impact from foreign exchange of approximately 1.5% on non-GAAP EPS.
- Uncertainties related to the proposed spin-off of certain businesses.
- Risks related to general industry conditions and competition.
- Impact of pharmaceutical industry regulation and health care legislation.
- Global trends toward health care cost containment.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
-0.4%
Avg return
Earnings day
-0.4%
Avg return
5 days after
+1.4%
Avg return
30 days after
51%
37 / 73 earnings
Positive
+8.0%
Q3 2021
Best reaction
-11.7%
Q3 2017
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.0% | +2.0% | +6.9% | |
| Q4 2025 | +2.2% | +7.6% | +2.4% | |
| Q3 2025 | -1.0% | -3.1% | +21.1% | |
| Q2 2025 | +1.2% | +1.0% | +5.2% | |
| Q1 2025 | +1.5% | +7.6% | -1.5% | |
| Q4 2024 | -9.1% | -12.5% | -5.8% | |
| Q3 2024 | -2.8% | -3.0% | -3.0% | |
| Q2 2024 | -11.5% | -9.8% | -8.1% | |
| Q1 2024 | +3.3% | +1.7% | +2.0% | |
| Q4 2023 | +4.7% | +5.1% | +5.1% | |
| Q3 2023 | -0.8% | -0.9% | -1.7% | |
| Q2 2023 | -0.9% | -1.5% | +2.2% | |
| Q1 2023 | +1.8% | +3.9% | -2.1% | |
| Q4 2022 | -3.8% | -1.2% | -0.1% | |
| Q3 2022 | +2.4% | +1.4% | +9.2% | |
| Q2 2022 | -2.1% | -4.0% | -2.2% | |
| Q1 2022 | +5.1% | +3.2% | +10.3% | |
| Q4 2021 | -4.2% | -6.2% | -5.1% | |
| Q3 2021 | +8.0% | +9.2% | -2.9% | |
| Q2 2021 | -1.9% | -2.5% | -2.6% | |
| Q1 2021 | -3.4% | -1.4% | -1.6% | |
| Q4 2020 | -2.0% | -2.9% | -5.4% | |
| Q3 2020 | -3.4% | -4.6% | +1.5% | |
| Q2 2020 | +4.5% | +3.4% | +8.4% | |
| Q1 2020 | -3.8% | -7.5% | -5.9% | |
| Q4 2019 | -3.0% | -3.1% | -7.0% | |
| Q3 2019 | +4.9% | +3.3% | +6.6% | |
| Q2 2019 | +0.6% | +2.4% | +5.1% | |
| Q1 2019 | +2.5% | +4.2% | +3.8% | |
| Q4 2018 | +3.3% | +4.0% | +9.7% | |
| Q3 2018 | -0.2% | +3.3% | +5.9% | |
| Q2 2018 | +1.2% | +2.3% | +7.9% | |
| Q1 2018 | -2.7% | -1.9% | +1.1% | |
| Q4 2017 | -5.8% | -6.6% | -9.2% | |
| Q3 2017 | -11.7% | -10.7% | -12.3% | |
| Q2 2017 | +0.3% | -0.4% | -1.2% | |
| Q1 2017 | +2.0% | +2.5% | +4.6% | |
| Q4 2016 | +3.5% | +3.4% | +7.2% | |
| Q3 2016 | +0.2% | -3.1% | +1.5% | |
| Q2 2016 | +0.4% | -1.3% | +7.6% | |
| Q1 2016 | -2.2% | — | — | |
| Q4 2015 | -3.6% | — | — | |
| Q3 2015 | +4.1% | — | — | |
| Q2 2015 | +2.7% | — | — | |
| Q1 2015 | +4.5% | — | — | |
| Q4 2014 | -3.0% | — | — | |
| Q3 2014 | -3.1% | — | — | |
| Q2 2014 | +0.2% | — | — | |
| Q1 2014 | +3.3% | — | — | |
| Q4 2013 | +0.5% | — | — | |
| Q3 2013 | -2.1% | — | — | |
| Q2 2013 | -0.3% | — | — | |
| Q1 2013 | -2.7% | — | — | |
| Q4 2012 | -5.6% | — | — | |
| Q3 2012 | -1.4% | — | — | |
| Q4 2011 | -1.0% | — | — | |
| Q2 2012 | +2.6% | — | — | |
| Q1 2012 | +2.0% | — | — | |
| Q3 2011 | -1.5% | — | — | |
| Q2 2011 | -1.6% | — | — | |
| Q1 2011 | -0.7% | — | — | |
| Q4 2010 | +0.8% | — | — | |
| Q3 2010 | -1.8% | — | — | |
| Q2 2010 | +0.8% | — | — | |
| Q1 2009 | -0.1% | — | — | |
| Q1 2010 | +0.1% | — | — | |
| Q4 2009 | +1.4% | — | — | |
| Q4 2007 | +1.4% | — | — | |
| Q3 2009 | -3.5% | — | — | |
| Q3 2008 | -3.5% | — | — | |
| Q2 2008 | +1.7% | — | — | |
| Q2 2009 | +1.7% | — | — | |
| Q4 2008 | +1.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro